Not only that, but the efficacy means those patients are going home. Cured.
Not slowly dying and clogging up the hospital system and draining it of funds.
These savings is why hospital purchasers and administrators will be focused on remestemcel-L and looking very favourably indeed at the next MSB products to be approved.
Accelerated Approval? Bring it on!
Not only that, but the efficacy means those patients are going...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.010(0.91%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.07 | $4.794M | 4.399M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14500 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 141676 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |